Particle.news
Download on the App Store
7 ARTICLES
·
3w ago

Louisiana’s Challenge to FDA’s Mifepristone Mail-Order Rule Heard in Federal Court

The Justice Department is urging the court to pause the case during the FDA’s renewed safety review of mifepristone.

Image
In this photo illustration, Mifepristone and misoprostol are seen at Wyoming's last abortion clinic, Wellspring Center, on March 10, 2025, in Casper, Wyoming.
Trump, Kennedy, and Makary surrounded by pills
Image

Overview

  • The U.S. District Court for the Western District of Louisiana held oral arguments on Feb. 24 in a suit targeting the FDA’s 2023 decision that permits telehealth prescribing and certified pharmacy dispensing of mifepristone.
  • Louisiana and plaintiff Rosalie Markezich seek a preliminary injunction to restore an in‑person visit requirement, citing allegations that pills ordered from out of state enabled coerced use.
  • Department of Justice filings argue the plaintiffs lack standing and ask the court to halt proceedings pending the FDA’s reopened evaluation of the drug’s safety.
  • Mifepristone manufacturers GenBioPro and Danco have intervened to defend the current rule and moved to dismiss the case, while anti-abortion groups, GOP attorneys general, and members of Congress filed briefs supporting Louisiana.
  • A ruling could influence nationwide access to telehealth abortion, which researchers report comprised nearly 30% of abortions in early 2025 and often involves mail delivery under state shield laws.